About MannKind Corp
MannKind Corp is a company based in Los Angeles (United States) founded in 1991.. MannKind Corp has raised $50 million across 8 funding rounds from investors including Deerfield. The company has 407 employees as of December 31, 2024. MannKind Corp has completed 3 acquisitions, including Qrumpharma, V-Go and scPharmaceuticals. MannKind Corp offers products and services including Afrezza, V-Go, and Technosphere. MannKind Corp operates in a competitive market with competitors including NGM Biopharmaceuticals, Rhythm Pharmaceuticals, Impel NeuroPharma, Corcept and ViaCyte, among others.
- Headquarter Los Angeles, United States
- Employees 407 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mannkind Corporation
-
Annual Revenue
$285.5 M43.5as on Dec 31, 2024
-
Net Profit
$27.59 M0as on Dec 31, 2024
-
EBITDA
$77.65 M373.61as on Dec 31, 2024
-
Total Equity Funding
$50 M (USD)
in 8 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Mar 01, 2021
- Investors
-
Employee Count
407
as on Dec 31, 2024
-
Investments & Acquisitions
Qrumpharma
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MannKind Corp
MannKind Corp is a publicly listed company on the NASDAQ with ticker symbol MNKD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MannKind Corp
MannKind Corp offers a comprehensive portfolio of products and services, including Afrezza, V-Go, and Technosphere. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhaled insulin powder for managing diabetes effectively.
Patch device for continuous insulin administration.
Platform for delivering medications via inhalation.
Unlock access to complete
Unlock access to complete
Software Development Team
26 people
Leadership Team
20 people
Human Resources and Administration
9 people
Scientific Team
9 people
Board Team
8 people
Legal and Compliance
4 people
Sales and Marketing
3 people
System Team
2 people
Unlock access to complete
Funding Insights of MannKind Corp
MannKind Corp has successfully raised a total of $50M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $200.0M
-
First Round
First Round
(01 Jan 2004)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Post-IPO - MannKind Corp | Valuation |
investors |
|
| Mar, 2018 | Amount | Post-IPO - MannKind Corp | Valuation |
investors |
|
| Jul, 2013 | Amount | Debt – Venture - MannKind Corp | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MannKind Corp
MannKind Corp has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Deerfield. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MannKind Corp
MannKind Corp has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Qrumpharma, V-Go and scPharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for diabetes and respiratory disorders are developed.
|
2014 | ||||
|
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
2013 | ||||
|
Product site of disposable, wearable insulin patch pump for continuous and bolus insulin
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - MannKind Corp
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mannkind Corp Comparisons
Competitors of MannKind Corp
MannKind Corp operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Rhythm Pharmaceuticals, Impel NeuroPharma, Corcept and ViaCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Intranasal delivery technology for CNS diseases is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cortisol modulators for the treatment of various diseases
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mannkind Corp
Frequently Asked Questions about MannKind Corp
When was MannKind Corp founded?
MannKind Corp was founded in 1991 and raised its 1st funding round 13 years after it was founded.
Where is MannKind Corp located?
MannKind Corp is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Who is the current CEO of MannKind Corp?
Michael Castagna is the current CEO of MannKind Corp.
Is MannKind Corp a funded company?
MannKind Corp is a funded company, having raised a total of $50M across 8 funding rounds to date. The company's 1st funding round was a Debt – Venture of $40M, raised on Jan 01, 2004.
How many employees does MannKind Corp have?
As of Dec 31, 2024, the latest employee count at MannKind Corp is 407.
What is the annual revenue of MannKind Corp?
Annual revenue of MannKind Corp is $285.5M as on Dec 31, 2024.
What does MannKind Corp do?
MannKind Corporation focuses on the discovery, development, and commercialization of a variety of therapeutic products through its proprietary drug delivery technology. The companys Technosphere formulation technology uses Technosphere Particles for pulmonary delivery of small molecules, peptides, and proteins directly by inhalation and thus helps in rapid drug absorption, bypassing the liver and also in enhancing bioavailability. The dry powder formulations are made with FDA approved excipients. The company also has proprietary products for inhalation profiling and single multi-use inhalers. The companys lead product includes Afrezza (inhalable ultra-rapid-acting insulin).
Who are the top competitors of MannKind Corp?
MannKind Corp's top competitors include Rhythm Pharmaceuticals, Corcept and NGM Biopharmaceuticals.
What products or services does MannKind Corp offer?
MannKind Corp offers Afrezza, V-Go, and Technosphere.
Is MannKind Corp publicly traded?
Yes, MannKind Corp is publicly traded on NASDAQ under the ticker symbol MNKD.
How many acquisitions has MannKind Corp made?
MannKind Corp has made 3 acquisitions, including Qrumpharma, V-Go, and scPharmaceuticals.
Who are MannKind Corp's investors?
MannKind Corp has 1 investor. Key investors include Deerfield.
What is MannKind Corp's ticker symbol?
The ticker symbol of MannKind Corp is MNKD on NASDAQ.